医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PeptiDream Announces Extension and Advancement of a Peptide Discovery Program

2014年10月03日 PM04:28
このエントリーをはてなブックマークに追加


 

TOKYO

PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”) (Tokyo:4587), announced today that one of the discovery programs initiated under the strategic alliance with Swiss-based Novartis has advanced into further optimization efforts, and will be extended and funded through an amendment to the original Strategic Alliance Agreement. PeptiDream identified macrocylic peptide candidates against an undisclosed target under the Macrocylic Peptide Drug Discovery Alliance, initiated in 2010 and extended in 2012. Candidates are undergoing optimization efforts in collaboration with Novartis, with PeptiDream using its PDPS system. The amendment provides additional research funding to cover additional PeptiDream resources focusing on the program’s optimization efforts and advancement.

[Comments from Patrick Reid, CSO, and Keiichi Masuya, COO, of PeptiDream Inc.]
“We are very excited with the program’s advancement. The additional funding will allow us to commit more resources toward the optimization efforts of this exciting program.”

CONTACT

Enquiries:
PeptiDream Inc.
Patrick C Reid,
+81-3-5790-9991 (Tokyo)
p-reid@peptidream.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™